Please assess the completion status of the following clinical trial:

Trial Title: Extract of Ginkgo Biloba and Tardive Dyskinesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged 18 to 60yrs~* Meeting Diagnostic and Statistical Manual of Mental Diseases, Fourth Edition(DSM-IV) criteria for schizophrenia or schizo-affective disorder~* Abnormal Involuntary Movement Scale (AIMS) score ≥2.~* Patients from whom informed, written consent is obtained.~* Patients who have been on a fixed dose of antipsychotic medication for at least 4 weeks prior to trial entry.~Exclusion Criteria:~* Significant neurological disorder other than TD~* Substance abuse~* Significant other medical illness~* Psychiatric disorder not stabilised~* Pregnancy or lactation~* Take antioxidants(such as Vitamin C)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Active treatment with EGb-761 capsules (80mg each capsule), 3 capsules each day for 12 weeks
- B (Type: PLACEBO_COMPARATOR): Matching placebo treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).